The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 08, 2021

Filed:

Jul. 16, 2017
Applicant:

Mapi Pharma Ltd., Ness Ziona, IL;

Inventors:

Yoram Sela, Ra'anana, IL;

Shai Rubnov, Tel Aviv, IL;

Assignee:

MAPI PHARMA LTD., Ness Ziona, IL;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/197 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/197 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2086 (2013.01); A61K 9/2846 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/5047 (2013.01); A61K 9/5078 (2013.01);
Abstract

The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.


Find Patent Forward Citations

Loading…